Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Completed · Phase 1/Phase 2
Conditions studied: Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia (CML), Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myeloproliferative Disorders
In brief
Determine the safety and tolerability of POL6326 when used as a single mobilization agent.
Key facts
- Study ID
- NCT01413568
- Run by
- Polyphor Ltd.
- People needed
- 38
- Starts
- 2012-04-01
- Expected to finish
- 2015-12-01
- Last updated by the study team
- 2016-02-26
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Kansas Cancer Center — Kansas City, Kansas, United States
- Washington University School of Medicine — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.